Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2021

View Archived Issues

New antifungals identified at Wigen Biomedicine Technology

SwanBio begins natural history study of adrenomyeloneuropathy to support SBT-101 development

Albireo describes new inhibitors of IBAT and/or NTCP

PB-201 shows safety and dose-dependent glycemic control in phase I trial

Janssen Pharmaceutica identifies new N-acetyl-beta-D-glucosaminidase inhibitors

Somatostatin SST5 receptor antagonists discovered at Kallyope

LG Chem patents sphingosine 1-phosphate receptor 1 agonists

Tissue factor knockout human placenta adherent stromal cells tested in MS model

Lilly describes first-in-human results with oxyntomodulin analogue LY-3305677

Study suggests teicoplanin can improve outcomes in COVID pneumonia patients

Retrotope initiates phase II study of RT-001 in progressive supranuclear palsy

Atea presents interim phase II data for AT-527 in hospitalized patients with COVID-19

Updated phase I/II data for galinpepimut-S plus Keytruda in WT1-positive ovarian cancer

Phase Ib data for NIS-793 plus spartalizumab in patients with advanced solid tumors

DksA1 inhibitors to suppress QS-mediated virulence of P. aeruginosa

ARO-DUX4 both prevents and reverses FSHD phenotype in mice

ISSCR: Genome-edited stem cells can make immune-evading transplants

ApoE4 allele as potential genetic risk factor for heart failure

CureVac reports final data from phase IIb/III study of COVID-19 vaccine candidate CVnCoV

Arrowhead begins dosing in phase IIb study of ARO-ANG3 in mixed dyslipidemia

Histogen opens phase I/II study of HST-003 for regeneration of knee cartilage

Pharmaxis reports inhibition of target enzymes in phase Ic study of PXS-5505 in myelofibrosis

Marinomed reports phase II topline data on Tacrosolv eye drops for allergic rhinoconjunctivitis

Oyster Point reports preclinical data on OC-01 and OC-02 against SARS-CoV-2 and variants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...